The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
Abstract
PURPOSE: To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals, Wilmington, DE), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with solid tumor types known to express or highly express EGFR. METHODS: This was an open-label, phase I, dose escalation safety/tolerability trial of oral ZD1839 (150 to 1,000 mg/d), administered once daily for 28-continuous-day cycles until disease progression or undue toxicity. RESULTS: Of 71 (69 assessable for safety; 58 for efficacy) patients at seven dose levels, most had non–small-cell lung (n = 39) or head and neck (n = 18) cancer, and 68 of 71 patients received prior cancer therapy (two or more regimens in 54 patients [78%]). Diarrhea and rash, the primary dose-limiting toxicities (DLTs), occurred at 800 mg. Frequent treatment-related grade 1/2 adverse events were diarrhea (55%), asthenia (44%), and acne-like follicular rash (46%). At doses ≥ 800 mg, 45% of patients required dose reductions. No increased or cumulative toxicity was observed over 250 patient-months of exposure. Pharmacokinetic analysis showed that steady-state occurred by day 7, interpatient exposure was more variable than intrapatient exposure, and variability of exposure did not change with dose. One patient experienced a partial response, but antitumor activity manifested mainly as prolonged stable disease (45% of patients ≥ 3 months, 22% ≥ 6 months, and 7.2% ≥ 1 year). No relationship between dose, response, or duration on study was observed. CONCLUSION: Rash and diarrhea, generally mild and tolerable at doses ≤ 600 mg/d, were DLTs at 800 mg/d (maximum-tolerated dose). Antitumor activity was observed at all doses. Pharmacokinetic analyses confirmed suitability of once-daily oral dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Kulik, G., Klippel, A., & Weber, M. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1595 · Cited by 1,040
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Wells, A. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00015-1 · Cited by 817
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Self-citationSirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
List, M. A., D'Antonio, L. L., Cella, D. F., Siston, A., Mumby, P., Haraf, D., & Vokes, E. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2294::aid-cncr17>3.0.co;2-s · Cited by 614
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Self-citationRude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Self-citationAkimoto, T., Hunter, N. R., Buchmiller, L., Mason, K. A., Ang, K. K., & Milas, L. (1999) · PubMed · Cited by 357
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., & Christian, M. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.265 · Cited by 331
Fontanini, G., Laurentiis, M. D., Vignati, S., Chinè, S., Lucchi, M., Silvestri, V., Mussi, A., Placido, S. D., Tortora, G., Bianco, A. R., et al. (1998) · PubMed · Cited by 306
Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., et al. (2000) · Oncology Reports · doi:10.3892/or.7.3.603 · Cited by 254
Veale, D., Kerr, N., Gibson, G., Kelly, P., & Harris, A. L. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.306 · Cited by 219
Volm, M., Rittgen, W., & Drings, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.106 · Cited by 178
Potential molecular prognostic markers in head and neck squamous cell carcinomas
Quon, H., Liu, F. F., & Cummings, B. J. (2001) · Head & Neck · doi:10.1002/1097-0347(200102)23:2<147::aid-hed1010>3.0.co;2-# · Cited by 170
Swaisland, H., Laight, A., Stafford, L. E., Jones, H., Morris, C. Q., Dane, A. L., & Yates, R. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00005 · Cited by 116
Self-citationGrowth factors and their receptors: new targets for prostate cancer therapy
Barton, J. E., Blackledge, G. R. P., & Wakeling, A. E. (2001) · Urology · doi:10.1016/s0090-4295(01)01253-5 · Cited by 107
ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT
Woodburn, J. R., Barker, A. J., Gibson, K. H., et al. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199709000-00044 · Cited by 66
The Epidermal Growth Factor Receptor in Breast Cancer
Fox, S. B., & Harris, A. L. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026399613946 · Cited by 63
Kris, M. G., Herbst, R. S., Rischin, D., LoRusso, P. M., Baselga, J. M., Hammond, L. A., Feyereislova, A., Ochs, J., & Averbuch, S. D. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80233-0 · Cited by 62
Self-citationKarp, D. D., Ferrante, K. J., Tensfeldt, T. G., Thurer, R. L., LoCicero, J., Huberman, M. S., Wirth, F., Hellman, R., Poulin, P., Silberman, S., et al. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80208-1 · Cited by 58
Cited by
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Self-citation
Metadata
- Authors
- Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., Ochs, J., & LoRusso, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-15
- Volume
- 20
- Issue
- 18
- Pages
- 3815-3825
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142661339
- Cited by
- 572
- References
- 30
- FWCI
- 59.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.